The Conversation (0)
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026.
In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board.
"We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Mark brings deep operational leadership and global life sciences experience at scale. His background will further strengthen the Supervisory Board's ability to provide effective oversight and support disciplined capital allocation."
"I would also like to express our sincere appreciation to Ross Levine for his outstanding service on the Supervisory Board over the last decade," Mr. Rusckowski said. "Ross is an esteemed physician-scientist whose scientific leadership and clinical perspectives have made a lasting contribution to QIAGEN. We wish him every success in his new leadership role and are grateful that he will continue to lead our Scientific Advisory Board, where his guidance remains critical to our innovation agenda."
Mark Stevenson has more than 30 years of experience in life science technology companies, with a strong focus on operational execution and global scale. He most recently served as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific. Earlier in his career, Mark Stevenson held senior leadership roles as President and Chief Operating Officer at Life Technologies and President and Chief Operating Officer at Applied Biosystems. He is currently an Operating Partner at Fivespan Partners and also serves on the board of directors of Ingersoll Rand, a publicly listed company in the United States.
Following these changes, the Supervisory Board continues to be comprised of eight members: Stephen H. Rusckowski (Chairman), Dr. Metin Colpan, Dr. Toralf Haag, Bert van Meurs, Eva van Pelt, Dr. Eva Pisa, Mark Stevenson and Elizabeth E. Tallett.
About QIAGEN
Qiagen N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com .
Forward-Looking Statement
Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as "believe", "hope", "plan", "intend", "seek", "may", "will", "could", "should", "would", "expect", "anticipate", "estimate", "continue", "target" or other similar words. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: Qiagen N.V.
Category: Corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20260126460580/en/
Investor Relations
e-mail: ir@QIAGEN.com
Corporate Communications
e-mail: pr@QIAGEN.com
